A stricter interpretation: the EPO and antibodies

The invention of the antibody hybridoma technology by Nobel prize winners Georges Köhler and César Milstein in 1975 paved the way to the development of therapeutic antibodies.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Biotechnology

EPO’s new examination guidelines: what you need to know

6 April 2021 The updated rules included important changes involving amino or nucleic acid sequences and antibodies, as Clare Roskell and Samantha Moodie of Mathys & Squire explain.

Big Pharma

Medical tech leads 2020 innovation at the EPO

16 March 2021 Healthcare innovation led patenting activity in 2020 as COVID-19 fuelled a rise in applications, a report by the European Patent Office has revealed.

Americas

Danish university sues Creative Biolabs over ‘antibody pirating’

9 December 2020 The University of Southern Denmark has accused biotech Creative Biolabs of infringing its patent-protected monoclonal antibody, HG-HYB 7-5.

More features

Killing the golden goose of US drug innovation: Follow the money (Part I)

UK gets new IP minister following cabinet reshuffle

Roche resolves cancer test dispute with Stanford affiliated startup

UK firm expands in Germany with more litigation hires

Sandoz blocked by UK court from seeking Xarelto profits

An update on patenting in Ukraine, Russia and Eurasia

The rise of pro-NPE and patent sentiment in the US

UPC sees rising small molecule litigation with Pfizer in the hot seat

A stricter interpretation: the EPO and antibodies

More on this story

Editor's picks

Editor's picks

More features